Absci Corp
ABSI3.000USD
+0.100+3.45%
Horário de mercado （ET）Cotações atrasadas em 15 min
382.62MValor de mercado
PerdaP/L TTM
Mais detalhes de Absci Corp Empresa
Absci Corporation is a data-first generative artificial intelligence (AI) drug creation company. The Company combines AI with scalable wet lab technologies to create biologics for patients. The Company’s Integrated Drug Creation platform unlocks the potential to accelerate time to clinic and increase the probability of success by simultaneously optimizing multiple drug characteristics important to both development and therapeutic benefit. With the data to train, the AI to create, and the wet lab to validate, its Integrated Drug Creation platform aims to engineer biologics. It is developing a diversified portfolio of programs with a focus on cytokine biology. It has three wholly owned internal pipeline programs focusing on cytokine biology, as well as several other undisclosed pipeline programs under evaluation. Its wholly owned pipeline programs include ABS-101, ABS-201, and ABS-301. The Company’s other pipeline programs include ABS-501 and additional drug creation programs.
Informações da empresa
Código da empresaABSI
Nome da EmpresaAbsci Corp
Data de listagemJul 22, 2021
CEOMr. Sean Mcclain
Número de funcionários156
Tipo de títulosOrdinary Share
Fim do ano fiscalJul 22
Endereço18105 Se Mill Plain Blvd
CidadeVANCOUVER
Bolsa de valoresNASDAQ Global Select Consolidated
PaísUnited States of America
Código postal98683
Telefone13609491041
Sitehttps://www.absci.com/
Código da empresaABSI
Data de listagemJul 22, 2021
CEOMr. Sean Mcclain
Executivos da empresa
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Sean Mcclain
Mr. Sean Mcclain
Chief Executive Officer, Founder, Director
Chief Executive Officer, Founder, Director
8.73M
+1.38%
Dr. Zachariah (Zach) Jonasson, Ph.D.
Dr. Zachariah (Zach) Jonasson, Ph.D.
Chief Financial Officer, Chief Business Officer
Chief Financial Officer, Chief Business Officer
133.62K
-3.74%
Mr. Andreas Busch, Ph.D.
Mr. Andreas Busch, Ph.D.
Chief Innovation Officer
Chief Innovation Officer
131.48K
+61.36%
Ms. Shelby J. Walker, J.D.
Ms. Shelby J. Walker, J.D.
Chief Legal Officer
Chief Legal Officer
59.30K
--
Ms. Karen K. Mcginnis, CPA
Ms. Karen K. Mcginnis, CPA
Independent Director
Independent Director
29.50K
+96.67%
Mr. Daniel A. (Dan) Rabinovitsj
Mr. Daniel A. (Dan) Rabinovitsj
Independent Director
Independent Director
14.50K
--
Ms. Mary T. Szela
Ms. Mary T. Szela
Director
Director
--
--
Mr. Frans Van Houten
Mr. Frans Van Houten
Independent Chairman of the Board
Independent Chairman of the Board
--
-100.00%
Prof. Dr. Menelas (Mene) Pangalos, Ph.D.
Prof. Dr. Menelas (Mene) Pangalos, Ph.D.
Independent Director
Independent Director
--
--
Dr. Joseph Sirosh, Ph.D.
Dr. Joseph Sirosh, Ph.D.
Independent Director
Independent Director
--
--
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Sean Mcclain
Mr. Sean Mcclain
Chief Executive Officer, Founder, Director
Chief Executive Officer, Founder, Director
8.73M
+1.38%
Dr. Zachariah (Zach) Jonasson, Ph.D.
Dr. Zachariah (Zach) Jonasson, Ph.D.
Chief Financial Officer, Chief Business Officer
Chief Financial Officer, Chief Business Officer
133.62K
-3.74%
Mr. Andreas Busch, Ph.D.
Mr. Andreas Busch, Ph.D.
Chief Innovation Officer
Chief Innovation Officer
131.48K
+61.36%
Ms. Shelby J. Walker, J.D.
Ms. Shelby J. Walker, J.D.
Chief Legal Officer
Chief Legal Officer
59.30K
--
Ms. Karen K. Mcginnis, CPA
Ms. Karen K. Mcginnis, CPA
Independent Director
Independent Director
29.50K
+96.67%
Mr. Daniel A. (Dan) Rabinovitsj
Mr. Daniel A. (Dan) Rabinovitsj
Independent Director
Independent Director
14.50K
--
Detalhamento da receita
Sem dados
Sem dados
Por Empresa
Por Região
Sem dados
Distribuição de ações
Atualizado em: ter, 24 de jun
Atualizado em: ter, 24 de jun
Investidores
Tipos de investidores
Investidores
Investidores
Proporção
Fidelity Management & Research Company LLC
12.75%
ARK Investment Management LLC
6.97%
McClain (Sean)
6.05%
Redmile Group, LLC
5.72%
The Vanguard Group, Inc.
4.47%
Other
64.04%
Investidores
Investidores
Proporção
Fidelity Management & Research Company LLC
12.75%
ARK Investment Management LLC
6.97%
McClain (Sean)
6.05%
Redmile Group, LLC
5.72%
The Vanguard Group, Inc.
4.47%
Other
64.04%
Tipos de investidores
Investidores
Proporção
Investment Advisor
36.08%
Investment Advisor/Hedge Fund
18.18%
Individual Investor
6.46%
Hedge Fund
4.02%
Corporation
3.29%
Research Firm
1.79%
Bank and Trust
0.24%
Venture Capital
0.21%
Pension Fund
0.02%
Other
29.72%
Participação acionária institucional
Atualizado em: ter, 1 de jul
Atualizado em: ter, 1 de jul
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2025Q2
307
100.37M
69.60%
-3.07M
2025Q1
316
100.15M
78.58%
-546.74K
2024Q4
298
92.04M
80.13%
-8.74M
2024Q3
280
90.06M
79.27%
-8.98M
2024Q2
257
91.26M
83.61%
+4.72M
2024Q1
236
84.09M
77.41%
+14.50M
2023Q4
202
58.01M
62.41%
-6.63M
2023Q3
196
57.87M
62.40%
-7.67M
2023Q2
191
58.28M
63.02%
-12.48M
2023Q1
181
65.82M
71.20%
-6.10M
Ver Mais
Atividade dos acionistas
Nome
Ações detidas
Proporção
Variação
Var. %
Data
Fidelity Management & Research Company LLC
18.39M
14.41%
+4.87M
+36.07%
Mar 31, 2025
ARK Investment Management LLC
10.96M
8.59%
+2.69M
+32.53%
Mar 31, 2025
McClain (Sean)
8.73M
6.84%
+119.00K
+1.38%
Mar 31, 2025
Redmile Group, LLC
8.25M
6.47%
--
--
Apr 25, 2025
The Vanguard Group, Inc.
4.69M
3.67%
-86.40K
-1.81%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
6.25M
4.9%
+325.67K
+5.50%
Mar 31, 2025
Phoenix Ventures Partners II LP.
4.75M
3.72%
-4.61M
-49.28%
Mar 31, 2025
Fred Alger Management, LLC
4.29M
3.37%
-2.21M
-33.99%
Mar 31, 2025
Columbia Wanger Asset Management, LLC
2.40M
1.88%
--
--
Mar 31, 2025
MFS Investment Management
2.31M
1.81%
+20.59K
+0.90%
Mar 31, 2025
Ver Mais
ETFs Relacionados
Atualizado em: sáb, 2 de ago
Atualizado em: sáb, 2 de ago
Nome
Proporção
ARK Genomic Revolution ETF
2.39%
WisdomTree BioRevolution Fund
0.95%
iShares Micro-Cap ETF
0.06%
Invesco Nasdaq Biotechnology ETF
0.04%
ProShares Ultra Nasdaq Biotechnology
0.04%
iShares Biotechnology ETF
0.03%
Proshares Ultra Russell 2000
0.01%
ProShares UltraPro Russell2000
0.01%
iShares Russell 2000 Growth ETF
0.01%
Schwab U.S. Small-Cap ETF
0.01%
Ver Mais
ARK Genomic Revolution ETF
Proporção2.39%
WisdomTree BioRevolution Fund
Proporção0.95%
iShares Micro-Cap ETF
Proporção0.06%
Invesco Nasdaq Biotechnology ETF
Proporção0.04%
ProShares Ultra Nasdaq Biotechnology
Proporção0.04%
iShares Biotechnology ETF
Proporção0.03%
Proshares Ultra Russell 2000
Proporção0.01%
ProShares UltraPro Russell2000
Proporção0.01%
iShares Russell 2000 Growth ETF
Proporção0.01%
Schwab U.S. Small-Cap ETF
Proporção0.01%
Dividendo
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Sem dados
Desdobramento de ações
Data
Tipo
Proporção
Sem dados
Data
Tipo
Proporção
Sem dados
